ClinicalTrials.gg
CompletedNCT02253914Updated Oct 1, 2014

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

A Phase 1 interventional study of BILR 355 BS, solution and BILR 355 BS, tablet in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
Male
01

Study summary

Study to determine the safety, tolerability and pharmacokinetics of BILR 355 BS plus low dose ritonavir in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males who meet the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead , clinical laboratory tests

    • No finding deviating from normal (except as noted below) and of clinical relevance
    • No evidence of a concomitant disease
  2. Age ≥18 years and \<60
  3. ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Exclusion criteria

Exclusion Criteria:

  1. Current and medically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Surgery of gastrointestinal tract (except appendectomy)
  3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  4. History of relevant orthostatic hypotension, fainting spells or blackouts
  5. Chronic or relevant acute infections
  6. History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  7. Intake of drugs with a long half-life (>24 hours) within one month prior to administration of study drug or during the trial
  8. Use of drugs within 10 days prior to administration or during the trial, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation
  9. Participation in another trial with an drug within one month prior to administration or during the trial
  10. Smoker
  11. Inability to refrain from smoking on trial days
  12. Alcohol abuse (more than 60 g/day)
  13. Drug abuse
  14. Recent blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
  15. Excessive physical activities (within 1 week prior to administration or during the trial)
  16. Any laboratory value outside the normal reference range that is of clinical relevance
  17. Inability to comply with dietary regimen of study centre
  18. Infected with or viruses (defined as either being hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody positive)
  19. -1 infected as defined by a positive HIV ELISA test
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
100 participants (actual)

Study arms

  • Experimental
    BILR 355 BS, solution

    escalating doses

    Drug: BILR 355 BS, solution · Drug: Ritonavir

  • Experimental
    BILR 355 BS, tablet

    escalating doses

    Drug: BILR 355 BS, tablet · Drug: Ritonavir

  • Placebo comparator
    Placebo

    Drug: Placebo

06

What researchers measure

Primary outcomes

  1. AUCτ (area under the concentration time curve of BILR 355 in plasma over one dosing interval at steady state)

    Time frame: up to day 11

  2. Cmax (maximum concentration of BILR 355 in plasma)

    Time frame: up to day 11

  3. Time for BILR 355 BS to achieve steady state

    Time frame: up to day 11

  4. Cmin,ss (trough concentration of BILR 355 BS in plasma at steady state)

    Time frame: up to day 11

  5. Incidence of dose limiting toxicity

    Time frame: up to day 21

Secondary outcomes

  1. tmax (time from dosing to the maximum concentration of BILR 355 in plasma)

    Time frame: up to day 11

  2. AUCτ (area under the concentration time curve of metabolite 402 in plasma over one dosing interval at steady state)

    Time frame: up to day 11

  3. Cmax (maximum concentration of metabolite 402 in plasma)

    Time frame: up to day 11

  4. Ae (amount of BILR 355 excreted in the urine over the time interval from 0 to the time of the last urine collection interval)

    Time frame: up to day 11

  5. Metabolite BILR 402 Ae (amount of BILR 402 excreted in the urine over the time interval from 0 to the time of the last urine collection interval)

    Time frame: up to day 11

  6. Number of subjects with adverse events

    Time frame: up to 42 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004 and a primary completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 1, 2014
Start
Feb 2004
Primary completionActual
Dec 2004
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02253914
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Feb 2004
Primary completion
Dec 2004
Last update
Oct 1, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 5,11-dihydro-11-ethyl-5-methyl-8-(2-(1-oxido-4-quinolinyl)ethyl)-6H-dipyrido(3,2-B,2',3'-E)(1,4)diazepin-6-one · Bilr 355 · Solutions · Ritonavir

Start the discussion